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The sensitivities and specificities of three immunoassays for the detection of herpes simplex virus type 2
(HSV-2)-specific immunoglobulin G antibodies in serum, including the one-strip rapid immunoblot assay
(RIBA; Chiron Corporation) and two indirect enzyme immunosorbent assays (EIA; Gull Laboratories and
Centocor), were compared by testing a panel of 1,250 serum samples from individuals attending an outpatient
clinic for sexually transmitted diseases. A qualitative agreement among the three assays was observed with
1,080 serum samples (86.4%); 291 of the serum samples (23.3%) were positive, 789 samples (63.1%) were
negative, and 170 serum samples (13.6%) gave a discordant result. Results were considered conclusive when a
concordant result was obtained with two of three assays. The sensitivities and specificities of the RIBA, the Gull
EIA, and the Centocor EIA proved to be 99.2, 99.7, and 89.9% and 97.1, 96.7, and 99.3%, respectively. These
results indicate that the Chiron RIBA and the Gull EIA are especially useful and reliable for the detection of
HSV-2-specific antibodies in serum.
Ranking after infections with Chlamydia trachomatis and
human papillomavirus, genital herpes is the third most com-
mon sexually transmitted disease (4). The majority of recurrent
genital herpes infections are caused by herpes simplex virus
type 2 (HSV-2). Seroepidemiological studies of the prevalence
of HSV-2-specific antibodies are especially important to de-
termine the impact of this infection among risk groups.
Furthermore, adequate identification of HSV-2-infected in-
dividuals is important to prevent transmission to partners
and neonates and to identify asymptomatic HSV-2 infec-
tions (9). Most of the epidemiological studies and clinical
diagnoses of HSV infections are based on virus isolation,
PCR, and Western blot (WB) (2, 3, 8) analyses. Both PCR
and virus isolation are of limited value, since they give pos-
itive scores only during active infection. Serological diagno-
sis of HSV-2 infections has been difficult, since distinction
between HSV-1- and HSV-2-specific antibodies in serum is
complicated by the high degree of cross-reactivity. Several
assays for the detection of HSV-1- and HSV-2-specific an-
tibodies in serum have been described, including WB anal-
ysis (2), immunodot blot analysis (6), and enzyme im-
munosorbent assay (EIA) analysis (5, 7, 10). However, the
“gold standard” for HSV-1- and HSV-2-specific serology to
date is WB analysis (2), which is performed predominantly
in specialized laboratories.
Recently, three rapid immunoassays, one rapid immuno-
blot assay (RIBA) and two EIAs, have become available.
The RIBA (Chiron Corporation, Emeryville, Calif.) is based
on nitrocellulose membranes blotted with HSV-1 and HSV-
2 recombinant proteins D (gD), two HSV-1-specific antigens
(gG1 and gB1), and one specific HSV-2 recombinant anti-
gen (gG2). The Gull HSV-2 immunoglobulin G (IgG) EIA
(Gull Laboratories, Salt Lake City, Utah) is based on plates
coated with affinity-purified, type-specific HSV-2 glycoprotein
G (gG). The Centocor Captia Select HSV-2-G EIA (Centocor,
Malvern, Calif.) is based on plates coated with purified HSV-2
recombinant baculovirus-expressed gG. In a retrospective
study, we compared the three assays, using a panel of 1,250
serum samples from individuals aged between 15 and 68
years who visited the outpatient clinic for sexually transmit-
ted diseases of the University Hospital Rotterdam between
February 1993 and February 1994. After collection, the se-
rum samples were stored at 220°C until use. All assays were
performed according to the instructions provided by the
manufacturers. Results were considered true values when
they agreed in at least two of the three assays tested. The
sensitivities, specificities, and positive and negative predic-
tive values of the three assays were determined in relation to
each of the respective assays and against the defined true
values. Serum samples with discordant results between the
assays were tested by WB as previously described (2). To
verify if the measured values between the assays were in
agreement with the expected values and not based on a
matter of chance, the results were statistically analyzed by
the k method (1).
Table 1 summarizes the results and gives calculations of the
overall agreement, sensitivity, and specificity, as well as positive
and negative predictive values for each of the respective assays
and for the true values. Comparison of the Chiron RIBA and
the Gull EIA results shows a concordance of 1,166 (93.3%),
with 358 positive samples, 806 negative samples, and 2 inde-
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terminate results. Discordant results were found among 84
serum samples; 22 samples scored positive in the Chiron RIBA
and negative in the Gull EIA, 22 scored positive in the Gull
EIA and negative in the Chiron RIBA, and 40 samples scored
indeterminate in both assays. The measure of agreement be-
tween these assays (k 5 0.852) was very good (1). Comparison
between the Chiron RIBA and the Centocor EIA demon-
strated an overall agreement of 87.9% (1,099 of 1,250), with
294 positive and 805 negative serum sample results. A total of
151 serum samples proved to be discordant for both assays.
The measure of agreement between these assays (k 5 0.731)
was good (1). Between both EIAs, the overall agreement
was 89.8% (1,122 of 1,250); 293 samples scored positive, 826
scored negative, and 3 scored indeterminate. Discordant
results were detected for 128 samples. The measure of
agreement between these assays (k 5 0.765) was good (1).
Concordant results with all three assays were obtained for
1,080 of the 1,250 serum samples (86.4%); a positive result
in all three assays was obtained with 291 serum samples
(23.3%), a negative result was obtained with 789 samples
(63.1%), and a discordant result was found for 170 serum
samples (13.6%). Ninety-three serum samples of the 170
samples with a discordant result were tested by WB. Forty-
seven (50.4%) of the 93 discordant samples scored positive
by WB. Of these 47 WB-positive serum samples, 37 (78.7%)
were positive by the RIBA, 23 (48.9%) were positive by the
Gull EIA, and 10 (21.2%) were positive by the Centocor
EIA. The calculated sensitivities of the Chiron RIBA against
the Gull EIA and Centocor EIA were 94.2 and 93.6%,
respectively. Sensitivities of 94.2 and 94.8% were obtained
with the Gull EIA against the Chiron RIBA and the Cen-
tocor EIA, respectively. The sensitivity of the Centocor
EIA was slightly lower than those of the Chiron RIBA and
the Gull EIA (83.5 and 82.3%, respectively). The variation
in specificity between the respective assays was less than
10% (92.9 to 98.1%). When the results of the respective
assays were determined in relation to the defined true val-
ues, the sensitivity of the RIBA was 99.2%, that of the Gull
EIA was 99.7% and that of the Centocor EIA was 89.9%.
The specificities of these assays varied between 96.7 and
98.2%.
Until recently, no commercial assays were available for the
detection of HSV-2-specific antibodies in human serum. The
WB was the only assay that could discriminate between
HSV-1- and HSV-2-specific antibodies but could not be per-
formed routinely in clinical laboratory settings for HSV-1 and
HSV-2 serodiagnosis. The availability of HSV-2-specific sero-
logical assays offers the opportunity for clinical and peripheral
diagnostic laboratories to confirm a clinical diagnosis of HSV-2
infection without using relatively time-consuming and rela-
tively expensive virus isolation methods. Our retrospective
studies have analyzed the potential utility of the three HSV-2
assays to ensure correct serodiagnosis of HSV-2 infection and
have shown slight differences in sensitivity and specificity. The
high degree of sensitivity and specificity of the Chiron RIBA
for the detection of HSV-2 antibodies in serum allows an
accurate serodiagnosis of HSV-2 infections in clinically sus-
pected cases. The advantage of this assay is that with one
nitrocellulose strip both HSV-1 and HSV-2 antibodies in
serum can be identified. In contrast with the Chiron RIBA,
which is particularly useful for analysis of limited numbers
of samples, the Gull EIA provides a rapid tool for large
seroepidemiological studies with comparable sensitivity and
specificity. Approximately 10% of the samples tested in this
study by the Chiron and the Gull immunoassays were not
detected by the Centocor assay. The specificity of the Cen-
tocor EIA is similar to those of the other assays. This study
clearly demonstrates that the results obtained with the Chi-
ron RIBA and the Gull EIA especially coincided very well
and that both can be used for serodiagnosis of HSV-2 in-
fections.
TABLE 1. Estimation of levels of agreement, sensitivities, specificities, and positive and negative predictive values
for three HSV-2 IgG-specific antibody assaysa
Assay and true
value
RIBA Gull EIA
No. of samples Overall
agreement
(%)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
No. of samples
Positive Indeterminate Negative Positive Indeterminate Negative
RIBA
Positive 358 9 22
Indeterminateb 9 2 20
Negative 22 2 806
Gull EIA 93.3 94.2 97.3 94.2 97.3
Positive 358 9 22
Indeterminateb 9 2 2
Negative 22 20 806
Centocor EIA 87.9 93.6 93.3 83.5 97.6
Positive 294 0 20 293 3 16
Indeterminateb 36 0 6 33 3 6
Negative 58 31 805 63 7 826
True value 95.2 99.2 97.1 93.5 99.6
Positive 360 0 3 360 3 1
Indeterminateb 3 2 0 0 5 0
Negative 25 29 828 29 5 847
a Each of the respective assays and the true values were considered the gold standard. PPV and NPV, positive and negative predictive values, respectively.
b Indeterminate results were not used to calculate overall agreement, sensitivity, specificity, and positive and negative predictive values.-
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TABLE 1—Continued
Gull EIA Centocor EIA
Overall
agreement
(%)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
No. of samples Overall
agreement
(%)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)Positive Indeterminate Negative
93.3 94.2 97.3 94.2 97.3 87.9 83.5 97.9 94.5 93.3
294 36 58
0 0 31
17 6 805
89.9 82.3 98.1 94.8 92.9
293 33 63
3 3 7
16 6 826
89.8 94.8 92.9 82.3 98.1
96.7 99.7 96.7 92.5 99.9 92.5 89.9 98.2 94.9 96.3
295 30 33
0 3 2
16 9 859
VOL. 36, 1998 NOTES 847
